Harvard Bioscience, Inc. (HBIO)

Over the past six months, Harvard Bioscience's stock has been impacted by several events. The company announced its Q3 2025 financial results, reporting revenues of $20.6 million. Preliminary Q4 2025 financial results and a positive 2026 outlook led to a stock price increase. The company announced its Q4 and full-year 2025 financial results, with Q4 revenue reaching $23.7 million. A reverse stock split was announced and enacted to regain compliance with Nasdaq's minimum bid price requirement. Harvard Bioscience participated in KeyBanc's Virtual Healthcare Forum. The company announced a manufacturing consolidation initiative. SEC filings indicated insider activities and BroadOak reported a 16% stake.

Harvard Bioscience's financial reporting indicates some demand seasonality, with Q1 2025 guidance mentioning "normal seasonality" as a factor. Demand for their products and services may fluctuate throughout the year, potentially influenced by academic cycles and funding allocation timelines.

Harvard Bioscience, Inc. (HBIO) develops, manufactures, and sells technologies, products, and services for life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company's product portfolio includes Fluidics/Molecular Technologies such as syringe and peristaltic infusion pumps, Cell Analysis tools like electroporation instruments, Physiology/Preclinical platforms for assessing physiological data, and Laboratory Equipment & Supplies.

Harvard Bioscience has a global presence with operations in North America, Europe, and China. Its geographical segments include the United States, Germany, China, the United Kingdom, and the Rest of the World. Principal manufacturing facilities are located in New Brighton, Minnesota (USA), Holliston, Massachusetts (USA), Reutlingen (Germany), Barcelona (Spain), and March (Germany).

Harvard Bioscience, founded in 1901, has been innovating technologies for life science research for over 120 years. The company is a global leader in manufacturing and distributing solutions to advance life science research, serving customers in over 100 countries. The company's strategic direction for 2026 focuses on transitioning to renewed revenue growth and margin expansion.

Harvard Bioscience, Inc. has a significant number of institutional owners, with 71 institutional owners and shareholders holding a total of 21,521,665 shares. Major institutional shareholders include AMH Equity Ltd, Weber Capital Management Llc /adv, and Vanguard Group Inc. Individual ownership accounts for 0.62% of the company, with James W. Green owning the most shares among individuals.